In a report published Friday, Cantor Fitzgerald reiterated its Hold rating and $38.00 price target on Cepheid (NASDAQ: CPHD). Cantor Fitzgerald noted, “CPHD continues to hit on target new product launches with the FDA clearance of the Xpert CT/NG test (announced yesterday after the close) before year-end 2012.